Pompanopeptin B–An Ideal Drug For Treating Thyroid Cancer

Authors

  • Sangeetha M Department of Microbiology, Kamaraj College, Tuticorin, Tamil Nadu, India.
  • Menakha.M Department of Biotechnology,MASS College of Arts and Science, Kumbakonam, Tamil Nadu,
  • S.Vijaya kumar Department of Botany and Microbiology, A.V.V.M.Sri Pushpam College, Poondi, Thanjavur, Tamil Nadu, India.

Keywords:

Thyroid cancer, cyanobacterial bioactive compounds, glide, in silico, Lyngbya confervoides, pompanopeptin B

Abstract

Thyroid cancer is a common endocrine related cancer with a higher incidence in women than in men. Thyroid tumors are classified on the basis of their histopathology as papillary, follicular, medullary, and undifferentiated or anaplastic. Thyroid hormone receptor alpha 1, (THRA1) is responsible for the development of tumour and resistance to chemotherapy. The side effects of the available drugs make the need for the necessity of new improved drugs. Cyanobacterial resource offers a great scope for discovery of new drugs for cancer. Cyanobacterial novel bioactive compounds with unique biological activities may be useful in finding the potential drugs with greater efficacy, specificity for the treatment of human diseases. The aim of the present study was to predict the anticancer drug from the members of the cyanobacteria. In silico molecular docking was carried out between the cyanobacterial bioactive compounds, and thyroid cancer causing receptor. The highest energy value was produced by the Pompanopeptin B with thyroid hormone receptor alpha 1. From the above results, it is concluded that Pompanopeptin B, an ideal cyanobacterial drug can be employed as axbest drug for treating thyroid cancer without any side effects.

Downloads

Download data is not yet available.

References

Grünwald, F., Biersack, H. J. and Grounwald, F. 2005. Thyroid cancer. Berlin: Springer. ISBN 3-540-22309-6. Page 10.

Gurib-Fakim A. 2006. Medicinal plants: traditions of yesterday and drugs of tomorrow. Molecular Aspects of Medicine.,27(1):1-93

Guiry, M.D.; Guiry, G.M.2008. "Lyngbya". AlgaeBase. World-wide electronic publication, National University of Ireland, Galway.

Blunt JW, Copp BR, Hu WP, Munro MHG, Northcotec PT, Prinsep MR. 2008. Marine natural products. Nat Prod Rep.,25:35–94

Namikoshi, M., and Rinehart, K.L. 1996 Bioactive compounds produced by cyanobacteria. J. Ind. Microbiol., 17:373-384.

Kitchen DB, Decornez H, Furr JR, Bajorath J.2004. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery 3: 935-949.

Lengauer T, Rarey M.1996. Computational methods for biomolecular docking. Curr Opin. Struct. Biol., 6: 402–406.

http://www.rcsb.org/

http://www.chemspider.com/

http://www.cbs.dtu.dk/services/TMHMM/

http://sts.bioe.uic.edu/castp/

Kasper, Dennis L; Braunwald, Eugene; Fauci, Anthony; et al. Harrison's Principles of Internal Medicine (16th ed.) 2005, New York: McGraw-Hill. ISBN 0-07-139140-1.

Azzaoui K, 2007 Modeling promiscuity based on in vitro safety pharmacology profiling data. Chem. Med. Chem.2:874–880.

Vincent S, Djulbegovic B. 2005.Oncology treatment recommendations can be supported only by 1–2% of high-quality published evidence. 31 (4): 319.

Published

2018-02-23
Statistics
95 Views | 51 Downloads
Citatons

How to Cite

Sangeetha M, Menakha.M, and S.Vijaya kumar. “Pompanopeptin B–An Ideal Drug For Treating Thyroid Cancer”. International Journal of Pharmaceutics and Drug Analysis, vol. 6, no. 2, Feb. 2018, pp. 332-8, https://ijpda.org/index.php/journal/article/view/378.

Issue

Volume-6, Issue-2, February-2018

Section

Research Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © Author(s) retain the copyright of this article.

Share |